Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
4860- Uro,    Urolithins–gut Microbial Metabolites with Potential Health Benefits
- Review, Nor, NA - Review, AD, NA - Review, Park, NA
*ROS↓, *Inflam↓, TumCG↓, *neuroP↑, *cardioP↑, *LDL↓, *BioAv↝, *BioAv↓, *BioAv↑, *SIRT1↑, *mTOR↑, *BDNF↑, *cognitive↑,
4857- Uro,    Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study
- in-vitro, ESCC, KYSE-30
tumCV↓, selectivity↑, TumCCA↑, ROS↑, Bcl-2↓, BAX↑, P21↑, MMP2↓, MMP9↓,
4870- Uro,    Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
- in-vivo, AD, NA
*cognitive↑, *Apoptosis↓, *neuroP↑, *Aβ↓, *AMPK↑, *NF-kB↓, *MAPK↓, *BACE↑, *neuroG↑, *Inflam↓, *memory↑,
4871- Uro,  DHA,  LT,    A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease
- in-vitro, AD, NA
*ATP↑, *Apoptosis↓,
4872- Uro,    Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity
- in-vitro, AD, HEK293
*DYRK1A↓, *antiOx↑, *Inflam↓, *neuroP↑, *memory↑, *p‑tau↓, *Aβ↓, *neuroP↑,
4873- Uro,    Urolithin A Inhibits Anterior Basolateral Amygdala to Ventral Hippocampal CA1 Circuit to Ameliorate Amyloid-β-Impaired Social Ability
- in-vivo, AD, NA
*Aβ↓, *cognitive↑,
4874- Uro,  EGCG,    A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease
- in-vivo, AD, NA
*motorD↑, *memory↑, *MitoP↑, *Aβ↓, *mitResp↑, *Nrf1↑, *PINK1↑, *PARK2↑, *ATG5↑, *Bcl-2↑, *H2O2↓, *ROS↓, *lipid-P↓, *mt-ATP↑,
4875- Uro,    Impact of the Natural Compound Urolithin A on Health, Disease, and Aging
- Review, AD, NA - Review, Stroke, NA - Review, ostP, NA - Review, IBD, NA
*MitoP↓, *Strength↑, *PINK1↑, *PARK2↑, *Inflam↓, *COX2↓, *IL1β↓, *IL6↓, *TNF-α↓, *OS↑, *cardioP↑, *memory↑, *neuroG↑, *neuroP↑, *Cartilage↑, *Inflam↓, *RenoP↑, *eff↑, *Dose↝, *Half-Life↑, *NRF2↑, *GutMicro↑,
4876- Uro,    Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management
- Review, Park, NA - Review, AD, NA
*Inflam↓, *antiOx↓, *neuroP↑, *p‑tau↓, *Aβ↓, *eff↑, *BioAv↓, *BioAv↑, *GSH↑, *SOD↑, *lipid-P↓, *Catalase↑, *GSR↑, *GPx↑, *ROS↓, *NRF2↑, *GutMicro↑, *Risk↓, *BBB↓, *NLRP3↓, *MAOA↓,
4877- Uro,    Urolithin-A Derivative UAS03 Improves Cognitive Deficits and Memory by Activating Nrf2 Pathways to Alleviate Oxidative Stress and Neuroinflammation
- in-vivo, AD, NA
*cognitive↑, *memory↑, *neuroP↑, *NRF2↑, *ROS↓, *Inflam↓, *IL1β↓, *TNF-α↓, *COX2↓,
4878- Uro,    Activation of the Gut–Brain Interaction by Urolithin A and Its Molecular Basis
- Review, AD, NA
*memory↑, *SIRT1↑, *cognitive↑, *BDNF↑, *Apoptosis↓, *neuroG↑,
4879- Uro,    Neuroprotective Effect of Urolithin A against Cerebellum Changes in Streptozotocin-Induced Alzheimer’s Disease Rat Model
- in-vitro, AD, NA
*neuroP↑,
4880- Uro,    Urolithins: A Prospective Alternative against Brain Aging
- Review, AD, NA
*cognitive↑, *memory↑, *antiOx↑, *BBB↑, *ROS↓, *lipid-P↓, *Catalase↑, *SOD↑, *GSR↑, *GPx↑, *CREB↑, *BDNF↑, *neuroP↑, *Inflam↓, *MitoP↑, *Aβ↓, *tau↓, *NLRP3↓, *SIRT1↑, *SIRT3↑,
4884- Uro,    A review of pomegranate supplementation: A promising remedial avenue for Alzheimer's disease
- Review, AD, NA
*antiOx↑, *neuroG↑, *Inflam↓, *cognitive↑,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,
4833- Uro,    Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
BioAv↝, TumAuto↝, TumCG↓, TumMeta↓, ChemoSen↑, Imm↑, RadioS↑, BioAv↑, other↝, eff↓, *antiOx↓, *Inflam↓, AntiCan↓, AntiAge↑, chemoP↑, *neuroP↑, *ROS↓, *cognitive↑, *lipid-P↓, *cardioP↑, *TNF-α↓, *IL6↓, GutMicro↑, TumCCA↑, Apoptosis↑, angioG↓, NF-kB↓, PI3K↓, Akt↓, Casp↑, survivin↓, TumCP↓, cycD1/CCND1↓, cMyc↑, BAX↑, Bcl-2↓, COX2↓, P53↑, p38↑, *ROS↓, *SOD↑, *GPx↑, SIRT1↑, FOXO1↑, eff↑, ChemoSen↑,
4834- Uro,    Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer
- Human, Pca, NA
eff↑, NK cell↑,
4835- Uro,    Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway
- in-vitro, SCC, NA
TumCD↑, ER Stress↑, Akt↓, mtDam↓, p‑mTOR↓, *BioAv↝, ROS↑, TumCCA↑, Apoptosis↑, ERK↓,
4836- Uro,    Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation
- in-vitro, Var, NA
FOXO1↑, TumCG↓, PD-1↓, TIM-3↓,
4837- Uro,    Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review
- Review, Var, NA
AntiCan↑, TumCCA↑, Apoptosis↑, TumAuto↑, *BioAv↝, *BioAv↑, RAS↓, ERK↓, AR↓, TumCP↓, PI3K↓, Akt↓, NF-kB↓, COX2↓, IL6↓, IL1β↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, P53↑, Casp3↑, PARP↑, ROS↓, toxicity↓,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,
4839- Uro,    Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
tumCV↓, Apoptosis↓, P53↑, P21↑, PUMA↑, NOXA↑, MDM2↓, XIAP↓,
4840- Uro,    Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer
- vitro+vivo, BC, NA
MMP↓, TumCP↓, Apoptosis↑, tumCV↓, ER-α36↝, *toxicity↓,
4841- Uro,    Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells
- in-vitro, CRC, HT29 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
TumCP↓, TumCCA↑, Apoptosis↑, P53↑, P21↑, Bcl-2↓, Cyt‑c↑, Casp↑, ROS↑, *ROS↓,
4842- Uro,    Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, MCF-7 - in-vitro, BC, 4T1
Inflam↓, IL6↓, TNF-α↓, eff↑, STAT3↓, TumCP↓, TumCMig↓,
4843- Uro,    The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide
- in-vitro, Pca, LNCaP
TumCP↓, eff↑, ChemoSen↝,
4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, TumCI↓, EMT↓, Snail↓, MDM2↑, P53↑, E-cadherin↑, N-cadherin↓, Vim↓,
4845- Uro,    The gut microbiota metabolite urolithin A, but not other relevant urolithins, induces p53-dependent cellular senescence in human colon cancer cells
- in-vitro, Colon, HCT116
TumCCA↑, P53↑, P21↑,
4846- Uro,    Urolithin A exerts anti-tumor effects on gastric cancer via activating autophagy-Hippo axis and modulating the gut microbiota
- in-vivo, GC, NA
TumCG↓, Hippo↑, Warburg↓, Apoptosis↑, GutMicro↑,
4847- Uro,    Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells
- in-vitro, CRC, SW-620
TumCP↓, TumCMig↓, MMP9↓, TumAuto↑, Apoptosis↑, TumCCA↓, TumMeta↓, ChemoSen↓,
4848- Uro,  OXA,    Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells
- in-vitro, Colon, HCT116
TumCG↓, ChemoSen↑, P53↝, P21↑,
4849- Uro,    Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway
- vitro+vivo, GC, NA
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, TumAuto↑, TumCG↓, chemoP↑, ChemoSen↑,
4850- Uro,    Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population
- Review, Var, NA
*BioAv↑, BioAv↑,
4851- Uro,    Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1
- in-vitro, OS, MG63
TumCMig↓, TumCI↓, TumCA↑, MMP2?, MMP9?,
4852- Uro,    Dietary Urolithin B Suppresses Lung Tumorigenesis Correlating with Autophagy Induction and Gut Microbiota Remodeling
- vitro+vivo, Lung, NA
TumCG↓, *GutMicro↑, *Inflam↓, *antiOx↑, AntiTum↑, TumCCA↑, Apoptosis↑,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,
4854- Uro,    Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)
- Review, Pca, NA
AR↓, ROS↓, Apoptosis↑, selectivity↑, Dose↑, MDA↓, SOD↑, GPx↑, ROS↑, Casp3↑, Casp9↑,
4855- Uro,    Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells
- in-vitro, Bladder, UMUC3
TumCCA↑, PI3K↓, Akt↓, MAPK↓,
4858- Uro,    The Metabolite Urolithin-A Ameliorates Oxidative Stress in Neuro-2a Cells, Becoming a Potential Neuroprotective Agent
- in-vitro, Nor, NA
*ROS?, *neuroP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSR↑, *monoA↓, *tyrosinase↓,
4616- VitA,RetA,  VitC,  VitD3,  VitE,  Rad  Vitamins and Radioprotective Effect: A Review
- Review, NA, NA
*radioP↑, *ROS↓,
4313- VitA,RetA,    Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology
- Review, AD, NA
*neuroP↑, memory↑, *Inflam↓, *neuroG↑, *cognitive↑, *Aβ↓, p‑tau↓, *BACE↓,
4312- VitB1/Thiamine,    Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease
- Review, AD, NA
*eff↑, *cognitive↑, *memory↑, *GlucoseCon↑, *Aβ↓, *Inflam↓, *antiOx↑, *p‑tau↓, *AGEs↓, *Dose↝,
4314- VitB1/Thiamine,    Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology
- Review, AD, NA
*Risk↓, *GlucoseCon↑, *cognitive↑, *ATP↑, *ROS↓, *NADPH↑, *Aβ↓, *APP↓, *BACE↓,
4310- VitB1/Thiamine,    Pharmacological thiamine (Vitamin B1) as a treatment for alzheimer’s disease
- Review, AD, NA
*other↝, *memory↑, *Inflam↓, *p‑tau↓,
4311- VitB1/Thiamine,    Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy
- in-vivo, AD, NA
*Aβ↓, *p‑tau↓, *ROS↓, *cognitive↑, *OS↑, *Mood↑, *neuroP↑, *Inflam↓, *NRF2↑, *PGC-1α↑, *AGEs↓, *4-HNE↓, *NQO1↑, *COX2↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *GSK‐3β↓,
4327- VitB1/Thiamine,    Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease
- Study, AD, NA
*Risk↓, *other↝,
1888- VitB1/Thiamine,  DCA,    High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate
- in-vitro, PC, SK-N-BE - NA, PC, PANC1
p‑PDH↓, GlucoseCon↓, lactateProd↓, MMP↓, Casp3↑, eff↑, PDKs↓, selectivity↑, TumCG↓, Dose∅, MMP↓, ROS∅, toxicity↑, antiOx↑,
4049- VitB1/Thiamine,    Vitamin B1 (thiamine) and dementia
- Review, AD, NA
*memory↑, *p‑tau↓, *cognitive↑, *Dose↝, *Dose↓, *Aβ↓, *other↝, *eff↑, *eff↑,
4050- VitB12,  VitD3,  VitE,    Nutrient intake, nutritional status, and cognitive function with aging
- Review, AD, NA
neuroP↑,
4037- VitB12,  FA,    Mechanistic Link between Vitamin B12 and Alzheimer’s Disease
- Review, AD, NA
*antiOx↑, *ROS↓, *GSH↑, *Inflam↓, *IL6↓, *TNF-α↓, *other↑, *other↑, *other↑, *Aβ↓, *memory↑, *p‑tau↓, *APP↓, *BACE↓, *ATP↑, *neuroP↑,

Showing Research Papers: 5801 to 5850 of 6114
Prev Page 117 of 123 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6114

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GPx↑, 1,   MDA↓, 1,   ROS↓, 2,   ROS↑, 5,   ROS∅, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 4,   mtDam↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   cMyc↑, 1,   GlucoseCon↓, 1,   lactateProd↓, 1,   p‑PDH↓, 1,   PDKs↓, 1,   SIRT1↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 2,   Apoptosis↓, 1,   Apoptosis↑, 12,   BAX↑, 3,   Bcl-2↓, 3,   Casp↑, 2,   Casp3↑, 3,   cl‑Casp3↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Hippo↑, 1,   MAPK↓, 1,   MDM2↓, 1,   MDM2↑, 2,   NOXA↑, 1,   p38↑, 1,   PUMA↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 3,   TumAuto↝, 1,  

DNA Damage & Repair ⓘ

P53↑, 6,   P53↝, 1,   p53 Wildtype↑, 1,   PARP↑, 2,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 5,   TumCCA↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 3,   ERK↓, 2,   FOXO1↑, 2,   IGF-1↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   PI3K↓, 4,   RAS↓, 1,   STAT3↓, 1,   TumCG↓, 9,   Wnt↓, 2,  

Migration ⓘ

E-cadherin↑, 3,   ER-α36↝, 1,   MMP2?, 1,   MMP2↓, 2,   MMP9?, 1,   MMP9↓, 3,   N-cadherin↓, 3,   Snail↓, 3,   Treg lymp↓, 1,   TumCA↑, 1,   TumCI↓, 4,   TumCMig↓, 7,   TumCP↓, 10,   TumMeta↓, 2,   Vim↓, 3,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   TAMS↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1β↓, 2,   IL6↓, 3,   Imm↑, 1,   Inflam↓, 2,   NF-kB↓, 3,   NK cell↑, 1,   PD-1↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

TIM-3↓, 1,  

Synaptic & Neurotransmission ⓘ

p‑tau↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 3,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 4,   ChemoSen↝, 1,   Dose↑, 1,   Dose∅, 1,   eff↓, 2,   eff↑, 5,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

AR↓, 2,   GutMicro↑, 2,   IL6↓, 3,   NOS2↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiCan↓, 1,   AntiCan↑, 1,   AntiTum↑, 1,   chemoP↑, 2,   memory↑, 1,   neuroP↑, 1,   OS↑, 1,   toxicity↓, 1,   toxicity↑, 1,  
Total Targets: 119

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

4-HNE↓, 1,   antiOx↓, 2,   antiOx↑, 6,   Catalase↑, 3,   GPx↑, 4,   GSH↑, 2,   GSR↑, 3,   H2O2↓, 1,   lipid-P↓, 5,   NQO1↑, 1,   Nrf1↑, 1,   NRF2↑, 4,   PARK2↑, 2,   ROS?, 1,   ROS↓, 12,   SIRT3↑, 1,   SOD↑, 4,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 3,   mt-ATP↑, 1,   mitResp↑, 1,   PGC-1α↑, 1,   PINK1↑, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   CREB↑, 1,   GlucoseCon↑, 2,   LDL↓, 1,   NADPH↑, 1,   SIRT1↑, 3,  

Cell Death ⓘ

Apoptosis↓, 3,   Bcl-2↑, 1,   MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 3,   other↝, 3,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   DYRK1A↓, 1,   MitoP↓, 1,   MitoP↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,   mTOR↑, 1,   neuroG↑, 5,   tyrosinase↓, 1,  

Migration ⓘ

APP↓, 2,   Cartilage↑, 1,  

Barriers & Transport ⓘ

BBB↓, 1,   BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   IL1β↓, 3,   IL6↓, 3,   Inflam↓, 16,   NF-kB↓, 2,   TNF-α↓, 5,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 3,   MAOA↓, 1,   monoA↓, 1,   tau↓, 1,   p‑tau↓, 7,  

Protein Aggregation ⓘ

AGEs↓, 2,   Aβ↓, 12,   BACE↓, 3,   BACE↑, 1,   NLRP3↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 5,   BioAv↝, 3,   Dose↓, 1,   Dose↝, 3,   eff↑, 5,   Half-Life↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 3,   IL6↓, 3,  

Functional Outcomes ⓘ

cardioP↑, 3,   cognitive↑, 13,   memory↑, 11,   Mood↑, 1,   motorD↑, 1,   neuroP↑, 14,   OS↑, 2,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 3,   Strength↑, 1,   toxicity↓, 2,  
Total Targets: 82

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page